The US Food and Drug Administration has approved the company’s investigational new drug (IND) application for CABA-201, a fully human CD19-CAR T cell investigational therapy that contains the 4-1BB protein, according to Cabaletta Bio, Inc., a clinical-stage biotechnology company focused…
Tag: IND application
An investigational new drug (IND) application for SNS-101, a conditionally active VISTA-blocking antibody, has been submitted to the US Food and Drug Administration (FDA) for a phase 1/2 clinical trial in patients with solid tumours, according to Sensei Biotherapeutics, Inc.,…